Indeed, anti-CD44 antibody can induce differentiation and apoptosis in leukemia and bladder cancer cells (33, 34), while CD133+ cancer cells can be targeted using an anti-CD133 antibody conjugated with cytotoxic drug (35). This evidence concerns the gene CD44 and urinary bladder cancer.